Thompson Davis & CO. Inc. Invests $214,000 in Biohaven Ltd. (NYSE:BHVN)

Thompson Davis & CO. Inc. bought a new position in Biohaven Ltd. (NYSE:BHVN) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 5,000 shares of the company’s stock, valued at approximately $214,000.

Other large investors have also recently made changes to their positions in the company. Public Employees Retirement System of Ohio bought a new stake in shares of Biohaven in the third quarter worth about $236,000. NJ State Employees Deferred Compensation Plan bought a new stake in Biohaven during the third quarter worth approximately $267,000. Constitution Capital LLC bought a new stake in Biohaven during the fourth quarter worth approximately $300,000. Weybosset Research & Management LLC increased its stake in Biohaven by 19.7% during the third quarter. Weybosset Research & Management LLC now owns 12,140 shares of the company’s stock worth $316,000 after acquiring an additional 2,000 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in Biohaven during the fourth quarter worth approximately $363,000. 88.78% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Gregory Bailey bought 25,503 shares of the stock in a transaction on Wednesday, April 24th. The stock was bought at an average price of $39.18 per share, for a total transaction of $999,207.54. Following the completion of the acquisition, the director now directly owns 1,600,071 shares in the company, valued at $62,690,781.78. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Vlad Coric bought 121,951 shares of the stock in a transaction on Monday, April 22nd. The stock was bought at an average price of $41.00 per share, for a total transaction of $4,999,991.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,788,417 shares in the company, valued at $73,325,097. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gregory Bailey acquired 25,503 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The shares were acquired at an average price of $39.18 per share, with a total value of $999,207.54. Following the acquisition, the director now owns 1,600,071 shares in the company, valued at approximately $62,690,781.78. The disclosure for this purchase can be found here. Insiders purchased a total of 196,234 shares of company stock worth $7,999,179 over the last 90 days. Company insiders own 16.00% of the company’s stock.

Biohaven Trading Down 2.6 %

Shares of NYSE BHVN traded down $1.02 during trading hours on Tuesday, reaching $38.81. The stock had a trading volume of 1,079,559 shares, compared to its average volume of 1,251,978. The firm has a market cap of $3.43 billion, a price-to-earnings ratio of -6.89 and a beta of 1.18. The business’s fifty day moving average price is $50.70 and its two-hundred day moving average price is $42.17. Biohaven Ltd. has a 52-week low of $12.96 and a 52-week high of $62.21.

Biohaven (NYSE:BHVN) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). Equities research analysts anticipate that Biohaven Ltd. will post -5.81 earnings per share for the current fiscal year.

Analyst Ratings Changes

BHVN has been the topic of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research note on Thursday, April 18th. Royal Bank of Canada reissued an “outperform” rating and set a $61.00 price objective on shares of Biohaven in a research note on Tuesday, April 9th. JPMorgan Chase & Co. upped their target price on Biohaven from $32.00 to $56.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. HC Wainwright upped their target price on Biohaven from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Finally, TD Cowen upped their target price on Biohaven from $35.00 to $55.00 and gave the company an “outperform” rating in a research note on Friday, March 1st. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $52.13.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.